ALKS
Alkermes
Earnings and EPS analysis
- Stocks
- Healthcare
- NASDAQ: ALKS
- Earnings
EPS in 2026 (TTM): $0.4
Last Report Period Date: Jun 30, 2026
Currently, ALKS's current EPS stands at $0.4, according to the most recent financial reports. For the year 2025, ALKS reported a per-share earnings of $1.47, which marks a decrease compared to the EPS of $2.22 recorded in 2024. ALKS recorded an EPS of $0 for the quarterly period ending on Jun 30, 2026.
ALKS earnings history
In 2025, Alkermes's EPS was $1.47, a decrease of 33.8% from $2.22 in 2024. For the fiscal quarter that ended on Jun 30, 2026, the per-share earnings was $0, reflecting a 100% decline compared to the same quarter a year earlier. For the twelve months ending June 2026, the EPS is $0.4. For the year 2024, the yearly earnings per share was $2.22, marking an increase of 3.7% compared to 2023.
ALKS EPS vs price chart
ALKS EPS growth history
Alkermes has registered a decrease in earnings per share of 100% over the past 12 months (YoY, quarterly).
ALKS Earnings Waterfall
ALKS Earnings vs Peers
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | 14.21 | 178.7% | 5.3% | N/A |
| NVS Novartis AG | 22.78 | 21.8% | 31.2% | 15.2% |
| AZN Astrazeneca plc | 23.33 | 45.4% | 46% | 22% |
| JNJ Johnson & Johnson | 30.02 | 90.6% | 17.7% | 14.8% |
| PFE Pfizer Inc | 35.26 | -3.5% | -37.4% | -3.7% |
| TEVA Teva- Pharmaceutical Industries Ltd | 57.97 | 184.8% | N/A | N/A |
| ALKS Alkermes plc | 123.63 | -33.8% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.